GreenLight Biosciences's operating income is $-160M.
Get informed when a big investor buys or sells
+ FollowAs of Mar 31, 2023
Trailing 12 months ending Mar 31, 2023
As of the most recent data (March 2023), GRNA shows a operating income of $-160M. That compares with $-29M in the prior-year period — down 438.0% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, GRNA's operating income is now $-160M (was $-29M) — a 438.0% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether GreenLight Biosciences is outperforming or lagging.
Tracking GRNA's operating income over time shows whether GreenLight Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $-160M That compares with $-29M in the prior-year period — down 438.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this operating income page, Stockcircle has GreenLight Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-160M) with ownership activity and broader fundamentals.